Guideline Summary for Selection of Botulinum Toxin Products for Glabellar Line Treatment

Mechanism of Action

• Both daxibotulinumtoxinA (Daxxify) and onabotulinumtoxinA (Botox) act by inhibiting acetylcholine release at the neuromuscular junction, producing temporary facial muscle paralysis. 1

Contraindications & Safety Considerations

• Botulinum toxin injections are contraindicated in pregnancy, patients with neuromuscular disorders, and individuals with a known allergy to botulinum toxin. 1
• Although rare, high‑concentration cosmetic injections carry a risk of iatrogenic botulism. 1

Dosing & Potency

• The unit doses of Daxxify and Botox are not interchangeable because of differences in formulation and potency profiles. 3

Cost & Treatment Frequency

• Because Daxxify’s effect lasts longer, patients typically require only two treatments per year versus three to four treatments with Botox, which may offset higher per‑treatment costs. 2

Clinical Decision Algorithm

When to Prefer Daxxify

• Select Daxxify for patients who prioritize the longest possible interval between treatments. 2
• Select Daxxify for patients who can attend clinic visits only twice per year. 2
• Select Daxxify when overall annual convenience and total cost are more important than the per‑treatment price. 2

When to Prefer Botox

• Select Botox for patients who wish to trial botulinum toxin therapy with a shorter commitment period. 2
• Select Botox when institutional formularies or insurance coverage favor its use. 3

Management of Treatment Resistance

• If clinical resistance to one botulinum toxin product develops, consider switching to an alternative formulation (e.g., abobotulinumtoxinA, incobotulinumtoxinA, or rimabotulinumtoxinB) after confirming that the issue is not due to inadequate dosing, improper injection technique, or incorrect muscle targeting. 3